Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer

References

• ShupnikMAGonadotropin gene modulation by steroids and gonado-tropin-releasing hormoneBiol Reprod19965422792868788177
   PubMed Web of Science ®Google Scholar
• ConnPMCrowleyWFJrGonadotropin-releasing hormone and its analogsAnnu Rev Med1994453914058198390
   PubMed Web of Science ®Google Scholar
• KakarSSGrizzleWENeillJDThe nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitaryMol Cell Endocrinol19941061–21451497534732
   PubMed Web of Science ®Google Scholar
• KottlerMLStarzecACarreMCLagardeJPMartinACounisRThe genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancerInt J Cancer19977145955999178813
   PubMed Web of Science ®Google Scholar
• MillerWRScottWNMorrisRFraserHMSharpeRMGrowth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonistNature198531359992312332982100
   PubMed Web of Science ®Google Scholar
• KériGBaloghASzökeBTeplánICsukaOGonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell lineTumour Biol199112261671902971
   PubMedGoogle Scholar
• BlankesteinMAHenkelmanMSKlijnJGMDirect inhibitor effect of a luteinising hormone-releasing hormone agonist on MCF-7 human breast cancer cellsEur J Cancer Clin Oncol19852112149314993938397
   PubMedGoogle Scholar
• FeketeMWittliffJLSchallyAVCharacteristics and distribution of receptors for D-Trp6-luteinizing hormone, somatostatin. epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancerJ Clin Lab Anal1989331371472569034
   PubMed Web of Science ®Google Scholar
• SrkalovicGSzendeBReddingTWGrootKSchallyAVReceptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinomaProc Sac Exp Biol Med19891923209218
   Web of Science ®Google Scholar
• MilovanovicSRRadulovicSSchallyAVEvaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumorBreast Cancer Res Treat19922421471588443402
   PubMed Web of Science ®Google Scholar
• StojilkovicSSCattKJExpression and signal transduction pathways of gonadotropin-releasing hormone receptorsRecent Prog Horm Res1995501612057740156
   PubMedGoogle Scholar
• NaorZHarrisDShachamSMechanism of GnRH receptor signalling: combinatorial cross-talk of Ca2+ and protein kinase CFront Neuroendocrinol19981911199465287
   PubMed Web of Science ®Google Scholar
• GründkerCVölkerPEmonsGAntiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G-protein alpha(I)-mediated activation of phosphotyrosine phosphataseEndocrinology200114262369238011356684
   PubMed Web of Science ®Google Scholar
• DreanYLLiuDWongAOXiongFHewCLSteroidogenic factor 1 and estradiol receptor act in synergism to regulate the expression of the salmon gonadotropin II beta subunit geneMol Endocrinol19961032172298833651
   PubMedGoogle Scholar
• XieWDuanRSafeSEstrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactionsEndocrinology199914012192279886828
   PubMed Web of Science ®Google Scholar
• LiCBriggsMRAhlbornTEKraemerFBLiuJRequirement of Sp1 and estrogen receptor alpha interaction in 17beta-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expressionEndocrinology200114241546155311250935
   PubMed Web of Science ®Google Scholar
• WangWDongLSavilleBSafeSTranscriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactionsMol Endocrinol19991381373138710446910
   PubMed Web of Science ®Google Scholar
• PaechKWebbPKuiperGGDifferential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sitesScience19972775331150815109278514
   PubMed Web of Science ®Google Scholar
• JakackaMItoMWeissJChienPYGehmBDJamesonJLEstrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathwayJ Biol Chem200127617136151362111278408
   PubMed Web of Science ®Google Scholar
• WattersJJCampbellJSCunninghamMJKrebsEGDorsaDMRaid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcriptionEndocrinology19971389403040339275096
   PubMed Web of Science ®Google Scholar
• BeatsonGTEdinMDOn the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative casesLancet18961483803162165
   Google Scholar
• PatersonRRussellMHClinical trials in malignant disease: part II breast cancer: value of irradiation of the ovariesJ Fac Radiol195910313013324546197
   PubMedGoogle Scholar
• WalkerKJWalkerRFTurkesAEndocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancerEur J Cancer Clin Oncol19892546516542523808
   PubMedGoogle Scholar
• NicholsonRIWalkerKJMcClellandRADixonARobertsonJFBlameyRWZoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancerJ Steroid Biochem Mol Biol19903769899952149510
   PubMed Web of Science ®Google Scholar
• RobertsonJFWalkerKJNicholsonRIBlameyRWCombined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolva-dex) therapy in premenopausal women with breast cancerBr J Surg19897612126212652532556
   PubMed Web of Science ®Google Scholar
• CohenITepperRFigerAFlexDShapiraJBeythYSuccessful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposureBreast Cancer Res Treat199955211912510481939
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study Group (IBCSG)Castiglione-GertschMO’NeillAAdjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trialJ Natl Cancer Inst200395241833184614679153
   PubMedGoogle Scholar
• DavidsonNEO’NeillAMVukovAMChemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)J Clin Oncol200523255973598216087950
   PubMed Web of Science ®Google Scholar
• ArriagadaRLêMGSpielmannMRandomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyAnn Oncol200516338939615677625
   PubMed Web of Science ®Google Scholar
• KaufmannMGrafEJonatWA randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premeno-pausal patients with primary breast cancer – GABG-IV B-93Eur J Cancer200743162351235817897821
   PubMed Web of Science ®Google Scholar
• BaumMHackshawAHoughtonJAdjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP studyEur J Cancer200642789590416545560
   PubMed Web of Science ®Google Scholar
• Adjuvant Breast Cancer Trials Collaborative GroupOvarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trialJ Natl Cancer Inst200799751652517405996
   PubMedGoogle Scholar
• RochéHKerbratPBonneterreJComplete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trialAnn Oncol20061781221122716731539
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 womenLancet1992339878571851345869
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupOvarian ablation in early breast cancer: overview of the randomised trialsLancet19963489036118911968898035
   PubMed Web of Science ®Google Scholar
• SharmaRHamiltonABeithJLHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenCochrane Database Syst Rev20084CD00456218843661
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• LHRH-Agonists in Early Breast Cancer Overview GroupCuzickJAmbroisineLUse of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trialsLancet200736995741711172317512856
   PubMed Web of Science ®Google Scholar
• EifelPAxelsonJACostaJNational Institutes of Health Consensus Development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000J Natl Cancer Inst2001931397998911438563
   PubMed Web of Science ®Google Scholar
• GoldhirschAGlickJHGelberRDCoatesASSennHJMeeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh International Conference on adjuvant therapy of primary breast cancerJ Clin Oncol200119183817382711559719
   PubMed Web of Science ®Google Scholar
• BlameyRWfor EUSOMAGuidelines on endocrine therapy of breast cancer EUSOMAEur J Cancer200238561563411916542
   PubMed Web of Science ®Google Scholar
• TolisGAckmanDStellosATumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonistsProc Natl Acad Sci U S A1982795165816626461861
   PubMed Web of Science ®Google Scholar
• ReddingTWSchallyAVInhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormoneProc Natl Acad Sci U S A1983805145914626219395
   PubMed Web of Science ®Google Scholar
• SchallyAVReddingTWComaru-SchallyAMInhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RHMed Oncol Tumor Pharmacother1984121091186242477
   PubMedGoogle Scholar
• NériCBlangyDSchatzBDrieuKBerebbiMMartinPMDirect inhibiting effects of [D-Trp6]gonadotropin-releasing hormone on the estrogen-sensitive progression of polyoma virus-induced mammary tumors in athymic miceCancer Res19905018589258972168284
   PubMed Web of Science ®Google Scholar
• GründkerCGünthertARHellriegelMEmonsGGonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cellsEur J Endocrinol2004151561962815538941
   PubMed Web of Science ®Google Scholar
• PasqualiniJRBlumberg-TickJNguyenBLEffect of triptorelin (Decapeptyl) combined with heparin on estradiol levels in MCF-7 mammary cancer cells after incubation with estrone sulfateActa Endocrinol (Copenh)199312932602628212992
   PubMedGoogle Scholar
• KlijnJGMDe JongFHTreatment with a luteinising hormone releasing hormone analogue (buserelin) in pre-menopausal patients with metastatic breast cancerLancet1982319828312131216
   Google Scholar
• KlijnJGDe JongFHLambertsSWBlankensteinMALHRH agonist treatment in clinical and experimental human breast cancerJ Steroid Biochem1985235B8678733935869
   PubMedGoogle Scholar
• PlowmanPNNicholsonRIWalkerKJRemission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICT 118630Br J Cancer1986549039092948537
   PubMed Web of Science ®Google Scholar
• SchwartzLGuiochetNKeilingRTwo partial remissions induced by a LHRH analogue in two postmenopausal women with metastatic breast cancerCancer19886212249825002973369
   PubMed Web of Science ®Google Scholar
• Nesković-KonstantinovićZBVuletićLBNikolić-StanojevićLITherapeutic and endocrine effects of Decapeptyl, synthetic LH-RH agonistic analogue in premenopausal women with metastatic breast cancer. A pilot phase II studyOncology1994511951018265112
   PubMed Web of Science ®Google Scholar
• MariniLIacopinoFSchinzariGRobustelli della CunaFSMantovaniGSicaGDirect antiproliferative effect of triptorelin on human breast cancer cellsAnticancer Res1994145A188118857847821
   PubMed Web of Science ®Google Scholar
• Sanchez-GarridoFComaru-SchallyAMSanchez del CuraGGonzales-EnriquezJSchallyAVClearance of lung metastases of breast carcinoma after treatment with triptorelin in postmenopausal womanLancet19953458953868
   Web of Science ®Google Scholar
• Garcia-GiraltEBeuzebocPDierasVPhase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancerAm J Clin Oncol19961954554588823473
   PubMed Web of Science ®Google Scholar
• CelioLMartinettiAFerrariLPremenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine studyAnticancer Res1999193B2261226810472341
   PubMed Web of Science ®Google Scholar
• GoldhirschAGelberRDCastiglioneMThe magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the International Breast Cancer Study GroupAnn Oncol1990131831882261364
   PubMed Web of Science ®Google Scholar
• BiancoARDel MastroLGalloCPrognostic role of amenorrhoea induced by adjuvant chemotherapy in premenopausal patients with early breast cancerBr J Cancer19916357998032039706
   PubMed Web of Science ®Google Scholar
• SwainSMJeongJHGeyerCEJrLonger therapy, iatrogenic amenorrhea, and survival in early breast cancerN Eng J Med20103622220532065
   PubMed Web of Science ®Google Scholar
• LambertiniMCampbellCBinesJAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): analysis from the ALTTO trial (BIG 2-06) [abstract]Ann Oncol201728suppl5
   Google Scholar
• ReganMMPaganiOFlemingGFAdjuvant treatment of pre-menopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trialsBreast20132261094110024095609
   PubMed Web of Science ®Google Scholar
• FrancisPAReganMMFlemingGFAdjuvant ovarian suppression in premenopausal breast cancerN Engl J Med2015372543644625495490
   PubMed Web of Science ®Google Scholar
• PaganiOReganMMWalleyBAAdjuvant exemestane with ovarian suppression in premenopausal breast cancerN Engl J Med2014371210711824881463
   PubMed Web of Science ®Google Scholar
• BernhardJLuoWRibiKAdjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patients reported outcomes in the TEXT and SOFT randomised trialsLancet Oncol201516784885826092816
   PubMed Web of Science ®Google Scholar
• FlemingGFrancisPALángIRandomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the SOFT trialOral presentation at: 2017 San Antonio Breast Cancer SymposiumDecember 5-9; 2017San Antonio, TX
   Google Scholar
• PaganiOReganMMFlemingGFRandomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trialsOral presentation at: 2017 San Antonio Breast Cancer SymposiumDecember 5-9; 2017San Antonio, TX
   Google Scholar
• ReganMMFrancisPAPaganiOAbsolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trialsJ Clinic Oncol2016341922212231
   Web of Science ®Google Scholar
• RossiEMorabitoADe MaioEEndocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancerJ Clin Oncol200826226427018086795
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG)1-98 Collaborative GroupThürlimannBKeshaviahAA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• BelletMGrayKPFrancisPATwelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. [Abstract]J Clin Oncol201634141584159326729437
   PubMed Web of Science ®Google Scholar
• Del MastroLBoniLMichelottiAEffect of the gonadotropin-releasing hormone analogue triptorelin on the occurence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trialJAMA2011306326927621771987
   PubMed Web of Science ®Google Scholar
• LambertiniMBoniLMichelottiAOvarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trialJAMA2015314242632264026720025
   PubMed Web of Science ®Google Scholar
• MooreHCUngerJMPhilipsKAGoserelin for ovarian protection during breast-cancer adjuvant chemotherapyNEJM20153721092393225738668
   PubMed Web of Science ®Google Scholar
• BuchholzSSeitzSSchallyAVTriple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibitionInt J Oncol200935478979619724914
   PubMed Web of Science ®Google Scholar
• SchubertAHawighorstTEmonsGGründkerCAgonists and antagonists of GnRH-I and-II reduce metastasis formation by triple-negative human breast cancer cells in vivoBreast Cancer Res Treat2011130378379021279682
   PubMed Web of Science ®Google Scholar
• AIOM-AIRTUM Working GroupThe number of Cancer in Italy [I numeri del Cancro in Italia]Il Pensiero Scientifico EditoreRome20167582
   Google Scholar
• StensheimHCvancarovaMMøllerBFossåSDPregnancy after adolescent and adult cancer: a population-based matched cohort studyInt J Cancer201112951225123621387311
   PubMed Web of Science ®Google Scholar
• LetourneauJMSmithJFEbbelEERacial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancerCancer2012118184579458822451228
   PubMed Web of Science ®Google Scholar
• RuddyKJGelberSITamimiRMProspective study of fertility concerns and preservation strategies in young women with breast cancerJ Clin Oncol201432111151115624567428
   PubMed Web of Science ®Google Scholar
• PartridgeAHGelberSPeppercornJWeb-based survey of fertility issues in young women with breast cancerJ Clin Oncol200422204174418315483028
   PubMed Web of Science ®Google Scholar
• LeeSJSchoverLRPartridgeAHAmerican Society of Clinical Oncology recommendations on fertility preservation in cancer patientsJ Clin Oncol200624182917293116651642
   PubMed Web of Science ®Google Scholar
• LambertiniMDel MastroLPescioMCCancer and fertility preservation: international recommendations from an expert meetingBMC Med2016141126728489
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in OncologyBreast Cancer2017 Available from https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• PeccatoriFAAzimHAJrOrecchiaRCancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324suppl 616017022904238
   PubMed Web of Science ®Google Scholar
• Paluch-ShimonSPaganiOPartridgeAHSecond international consensus guidelines for breast cancer in young women (BCY2)Breast201626879927017247
   PubMed Web of Science ®Google Scholar
• LorenAWManguPBBeckLNFertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201331192500251023715580
   PubMed Web of Science ®Google Scholar
• Italian Association of Medical Oncology (AIOM)Clinical Practice Guideline on Fertility Preservation in Cancer Patients2016 Available from http://www.aiom.it/professionisti/documenti-scientifici/linee-guida/2016_LGAIOM_Preserv_fertil.pdf
   Google Scholar
• BigliaNTorrisiRD’AlonzoMCodacci PisanelliGRotaSPeccatoriFAAttitudes on fertility issues in breast cancer patients: an Italian surveyGynecol Endocrinol201531645846425982361
   PubMed Web of Science ®Google Scholar
• MooreHCFUngerJMPhillipsKAFinal analysis of SWOG S0230/Prevention of early menopause study (POEMS)Poster presentation at: 2017 San Antonio Breast Cancer SymposiumDecember 5-9; 2017San Antonio, TX
   Google Scholar
• LambertiniMCeppiMPoggioFOvarian suppression using luteinizing hormone releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studiesAnn Oncol201526122408241926347105
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschATailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• LeonardRCFAdamsonDJABertelliGGnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trialAnn Oncol20172881811181628472240
   PubMed Web of Science ®Google Scholar
• GerberBvon MinckwitzGStehleHEffect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO studyJ Clin Oncol2011292334234121537042
   PubMed Web of Science ®Google Scholar
• MunsterPNMooreAPIsmail-KhanRRandomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancerJ Clin Oncol201230553353822231041
   PubMed Web of Science ®Google Scholar
• LambertiniMMooreHCFLeonardRCFPooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients [abstract]. San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TXCancer Res2018784 Suppl abstract GS4-01
   Web of Science ®Google Scholar
• Del MastroLLambertiniMGonadotropin releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?Ann Oncol20172881683168528838207
   PubMed Web of Science ®Google Scholar
• LambertiniMBoniLMichelottiALong-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients [abstract]J Clin Oncol20143226 abstract105
   Web of Science ®Google Scholar
• ElgindyEAEl-HaiegDOKhorshidOMGonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trialObstet Gynecol20131211788623262931
   PubMed Web of Science ®Google Scholar